The 45-year story of the development of an anti-aldosterone more specific than spironolactone.

@article{Mnard2004The4S,
  title={The 45-year story of the development of an anti-aldosterone more specific than spironolactone.},
  author={Jo{\"e}l M{\'e}nard},
  journal={Molecular and cellular endocrinology},
  year={2004},
  volume={217 1-2},
  pages={45-52}
}
  • Joël Ménard
  • Published 2004 in Molecular and cellular endocrinology
At the early stage of its development in 1957, the daily dose of spironolactone necessary to improve various pathological conditions was not precisely determined and dose-dependent sexual side effects limited its long-term use. Prescription of high daily doses and absence of selectivity for the mineralocorticoid receptor explain these limitations. The 9-11alpha epoxy group added to mexrenone by the Ciba-Geigy chemists in 1984 and improved chemical synthesis at Searle, permitted the original… CONTINUE READING
19 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

Similar Papers

Loading similar papers…